Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent said it will manufacture Galapagos’ clinical-stage CAR T therapy, dubbed GLPG5101 ...